Overview

Study of Weekly Genexol®-PM Plus Gemcitabine in Subjects With Recurrent and Metastatic Adenocarcinoma of the Pancreas

Status:
Unknown status
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
Phase II Study of Weekly Genexol®-PM Plus Gemcitabine in Subjects With Recurrent and Metastatic Adenocarcinoma of the Pancreas.
Phase:
Phase 2
Details
Lead Sponsor:
Samyang Biopharmaceuticals Corporation
Treatments:
Gemcitabine
Paclitaxel
Pancreatin
Pancrelipase